Back to top

INmune Bio's CaRe PC Trial of INKmune in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment | INMB Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

INmune Bio, Inc. (INMB)